429 related articles for article (PubMed ID: 28499525)
1. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
[TBL] [Abstract][Full Text] [Related]
2. Proandrogenic and Antiandrogenic Progestins in Transgender Youth: Differential Effects on Body Composition and Bone Metabolism.
Tack LJW; Craen M; Lapauw B; Goemaere S; Toye K; Kaufman JM; Vandewalle S; T'Sjoen G; Zmierczak HG; Cools M
J Clin Endocrinol Metab; 2018 Jun; 103(6):2147-2156. PubMed ID: 29672753
[TBL] [Abstract][Full Text] [Related]
3. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
[TBL] [Abstract][Full Text] [Related]
4. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
[TBL] [Abstract][Full Text] [Related]
5. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF
Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345
[TBL] [Abstract][Full Text] [Related]
6. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
[TBL] [Abstract][Full Text] [Related]
7. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis.
Tack LJ; Craen M; Dhondt K; Vanden Bossche H; Laridaen J; Cools M
Biol Sex Differ; 2016; 7():14. PubMed ID: 26885361
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Cyproterone Acetate Treatment for Transgender Women.
Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y
J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757
[TBL] [Abstract][Full Text] [Related]
9. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.
Gava G; Cerpolini S; Martelli V; Battista G; Seracchioli R; Meriggiola MC
Clin Endocrinol (Oxf); 2016 Aug; 85(2):239-46. PubMed ID: 26932202
[TBL] [Abstract][Full Text] [Related]
10. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.
Charitidou C; Farmakiotis D; Zournatzi V; Pidonia I; Pegiou T; Karamanis N; Hatzistilianou M; Katsikis I; Panidis D
Atherosclerosis; 2008 Feb; 196(2):958-65. PubMed ID: 17418849
[TBL] [Abstract][Full Text] [Related]
11. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.
Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC
Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of antiandrogens and feminization in transgender women.
Angus LM; Nolan BJ; Zajac JD; Cheung AS
Clin Endocrinol (Oxf); 2021 May; 94(5):743-752. PubMed ID: 32926454
[TBL] [Abstract][Full Text] [Related]
13. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.
Nota NM; Dekker MJHJ; Klaver M; Wiepjes CM; van Trotsenburg MA; Heijboer AC; den Heijer M
Andrologia; 2017 Aug; 49(6):. PubMed ID: 27561756
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals.
Bunck MC; Giltay EJ; Diamant M; Gooren LJ; Teerlink T
Atherosclerosis; 2009 Sep; 206(1):245-50. PubMed ID: 19324362
[TBL] [Abstract][Full Text] [Related]
15. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
17. Changes of Vitamin D-Binding Protein, and Total, Bioavailable, and Free 25-Hydroxyvitamin D in Transgender People.
Chen H; Wiepjes CM; van Schoor NM; Heijboer AC; de Jongh RT; den Heijer M; Lips P
J Clin Endocrinol Metab; 2019 Jul; 104(7):2728-2734. PubMed ID: 30785996
[TBL] [Abstract][Full Text] [Related]
18. Variation in sensitivity and rate of change in body composition: steps toward individualizing transgender care.
van Velzen DM; Nota NM; Simsek S; Conemans EB; T'Sjoen G; den Heijer M
Eur J Endocrinol; 2020 Nov; 183(5):529-536. PubMed ID: 33071222
[TBL] [Abstract][Full Text] [Related]
19. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study.
Vita R; Settineri S; Liotta M; Benvenga S; Trimarchi F
Maturitas; 2018 Jan; 107():92-96. PubMed ID: 29169588
[TBL] [Abstract][Full Text] [Related]
20. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V
J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
